MX2021009921A - Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma. - Google Patents
Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma.Info
- Publication number
- MX2021009921A MX2021009921A MX2021009921A MX2021009921A MX2021009921A MX 2021009921 A MX2021009921 A MX 2021009921A MX 2021009921 A MX2021009921 A MX 2021009921A MX 2021009921 A MX2021009921 A MX 2021009921A MX 2021009921 A MX2021009921 A MX 2021009921A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained
- release
- lipid
- preformulation
- pharmaceutical composition
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 5
- 238000013268 sustained release Methods 0.000 title abstract 4
- 239000012730 sustained-release form Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000243 solution Substances 0.000 title abstract 3
- 238000002347 injection Methods 0.000 title abstract 2
- 239000007924 injection Substances 0.000 title abstract 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract 3
- 150000001982 diacylglycerols Chemical class 0.000 abstract 2
- -1 sorbitan unsaturated fatty acid esters Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000004973 liquid crystal related substance Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 229940042585 tocopherol acetate Drugs 0.000 abstract 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El resultado obtenido mediante la realización de la prueba de liberación in vitro como es descrita anteriormente es mostrado en la FIG. 6. A partir del resultado de la FIG. 6, puede ser confirmado que la composición farmacéutica inyectable de liberación sostenida en la forma de una solución de lípidos obtenida de acuerdo con la presente invención exhibe un patrón de liberación sostenida eficaz durante un largo período de tiempo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190018619A KR102186704B1 (ko) | 2019-02-18 | 2019-02-18 | 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물 |
PCT/KR2020/002182 WO2020171491A1 (ko) | 2019-02-18 | 2020-02-17 | 서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009921A true MX2021009921A (es) | 2021-10-13 |
Family
ID=72144366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009921A MX2021009921A (es) | 2019-02-18 | 2020-02-17 | Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220125888A1 (es) |
EP (1) | EP3928762A4 (es) |
JP (1) | JP7457727B2 (es) |
KR (1) | KR102186704B1 (es) |
CN (1) | CN113490487B (es) |
AU (1) | AU2020225991A1 (es) |
CA (1) | CA3130252A1 (es) |
MX (1) | MX2021009921A (es) |
WO (1) | WO2020171491A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021162532A2 (ko) * | 2020-02-14 | 2021-08-19 | 주식회사 지투지바이오 | Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 |
KR20230065921A (ko) * | 2021-11-05 | 2023-05-12 | (주)아이엠디팜 | 신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물 |
KR20230115591A (ko) * | 2022-01-27 | 2023-08-03 | 주식회사 티온랩테라퓨틱스 | 초기 방출 제어된 지질 융합 데포 조성물 및 이의 제조방법 |
CN117180281B (zh) * | 2023-11-08 | 2024-02-06 | 山东则正医药技术有限公司 | 棕榈酸帕利哌酮制剂及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
JP4083818B2 (ja) * | 1997-06-06 | 2008-04-30 | ディポメド,インコーポレイティド | 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形 |
SE9703458D0 (sv) | 1997-09-25 | 1997-09-25 | Pharmacia & Upjohn Ab | Nicotine compositions and methods of formulation thereof |
US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
EP1682091B1 (en) | 2003-11-07 | 2017-03-29 | Camurus Ab | Compositions of lipids and cationic peptides |
ES2309766T3 (es) | 2004-06-04 | 2008-12-16 | Camurus Ab | Formulaciones liquidas de liberacion lenta. |
KR101494594B1 (ko) * | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
KR101586790B1 (ko) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
KR101586789B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
CN106491519B (zh) * | 2016-12-09 | 2020-01-21 | 广州中大南沙科技创新产业园有限公司 | 局部麻醉药的立方液晶原位凝胶注射剂及其制备方法 |
KR102096391B1 (ko) * | 2019-10-11 | 2020-04-06 | (주)아이엠디팜 | 액상결정 구조체를 형성하는 오메가-3-지방산 조성물 |
-
2019
- 2019-02-18 KR KR1020190018619A patent/KR102186704B1/ko active IP Right Grant
-
2020
- 2020-02-17 WO PCT/KR2020/002182 patent/WO2020171491A1/ko active Application Filing
- 2020-02-17 JP JP2021548193A patent/JP7457727B2/ja active Active
- 2020-02-17 CN CN202080015053.4A patent/CN113490487B/zh active Active
- 2020-02-17 EP EP20758601.7A patent/EP3928762A4/en active Pending
- 2020-02-17 AU AU2020225991A patent/AU2020225991A1/en active Pending
- 2020-02-17 MX MX2021009921A patent/MX2021009921A/es unknown
- 2020-02-17 CA CA3130252A patent/CA3130252A1/en active Pending
- 2020-02-17 US US17/310,689 patent/US20220125888A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7457727B2 (ja) | 2024-03-28 |
KR20200100392A (ko) | 2020-08-26 |
CN113490487A (zh) | 2021-10-08 |
EP3928762A1 (en) | 2021-12-29 |
US20220125888A1 (en) | 2022-04-28 |
AU2020225991A1 (en) | 2021-09-02 |
CA3130252A1 (en) | 2020-08-27 |
CN113490487B (zh) | 2023-04-18 |
JP2022520858A (ja) | 2022-04-01 |
WO2020171491A1 (ko) | 2020-08-27 |
EP3928762A4 (en) | 2022-11-16 |
KR102186704B1 (ko) | 2020-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009921A (es) | Preformulacion de lipidos de liberacion sostenida y composicion farmacetica de liberacion sostenida inyectable en la forma de una solucion de lipidos que contiene a la misma. | |
MX351430B (es) | Pre-concentrado lipídico de liberación sostenida de una sustancia farmacológicamente activa y una composición farmacéutica que comprende el mismo. | |
Weller et al. | Cytoplasmic lipid bodies of neutrophils: formation induced by cis-unsaturated fatty acids and mediated by protein kinase C. | |
Philipson et al. | Effects of fatty acids on Na+-Ca2+ exchange and Ca2+ permeability of cardiac sarcolemmal vesicles. | |
PH12015500936B1 (en) | Sustained-release lipid pre-concentrate of gnrh analogues and pharmaceutical composition comprising the same | |
PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
EA200700389A1 (ru) | Стабильный при хранении инфузионный раствор дигидроптеридинонов | |
UA102477C2 (en) | Capsule composition | |
KR910000101A (ko) | 효소형성 억제제 | |
EA201490921A1 (ru) | Устойчивые составы с контролируемым высвобождением | |
US20230146709A1 (en) | Therapeutic use of compounds | |
JO3598B1 (ar) | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني | |
TR200102861T2 (tr) | Uzun zincirli trigliseridler ve lipofilik surfaktantları içeren oral farmasötik kompozisyonlar. | |
IL291055B2 (en) | Stable formulations of lipids and liposomes | |
ES2923149T3 (es) | AceFaPC para el tratamiento de enfermedades dependientes de la acetilcolina | |
PE20011223A1 (es) | Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico | |
NO20082181L (no) | Formuleringer av Fispemifen | |
Myers et al. | Studies on ali-esterases and other lipid-hydrolysing enzymes. 1. Inhibition of the esterases and acetoacetate production of liver | |
PE20080766A1 (es) | Sales de benzimidazolil piridil eteres y formulaciones que las contienen | |
RU2014149705A (ru) | Производные стеринов и их применение для лечения заболеваний, связанных с трансформированными астроцитными клетками, или для лечения злокачественных заболеваний крови | |
GB1097531A (en) | Improvements in or relating to the preparation of cyclopentane derivatives | |
Brain et al. | Actions of phospholipase-A on mast-cell histamine release and paw oedema in the rat [proceedings]. | |
KR910000102A (ko) | 효소형성 억제제 | |
Veryser et al. | The influence of the acyl chain on the transdermal penetration-enhancing effect of synthetic phytoceramides | |
MX2021012356A (es) | Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad. |